The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia

Oncogene

Volumn 35, Issue 15, 2016, Pages 1965-1976

  Sotoca, A M ^a   Prange, K H M ^a   Reijnders, B ^a   Mandoli, A ^a   Nguyen, L N ^a   Stunnenberg, H G ^a   Martens, J H A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASB2 PROTEIN; BETA CATENIN; CATENIN BETA1; CD11B ANTIGEN; CD15 ANTIGEN; CD18 ANTIGEN; CD34 ANTIGEN; DNA FRAGMENT; FUSED IN SARCOMA PROTEIN; GADD45B PROTEIN; HERMES ANTIGEN; HIC1 PROTEIN; HLA DR ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; LMO2 PROTEIN; LYL1 PROTEIN; MESSENGER RNA; MICROSOMAL AMINOPEPTIDASE; MYELOPEROXIDASE; PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOID X RECEPTOR; RNA POLYMERASE II; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR TAL1; UNCLASSIFIED DRUG; MULTIPROTEIN COMPLEX; ONCOPROTEIN; PROTEIN BINDING; PROTO-ONCOGENE PROTEIN SPI-1; RARA PROTEIN, HUMAN; RETINOIC ACID RECEPTOR; RNA BINDING PROTEIN FUS; SMALL INTERFERING RNA; TLS-ERG FUSION PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; BONE MARROW CELL; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CELL COUNT; CELL CYCLE CHECKPOINT; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL LEVEL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; EXON; FUSION GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE REPRESSION; GENE SEQUENCE; GENE SILENCING; GENE TRANSLOCATION; GENETIC ANALYSIS; GENOME; GROWTH REGULATION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEUKEMIA CELL LINE; LEUKEMOGENESIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; RECIPROCAL CHROMOSOME TRANSLOCATION; RNA METABOLISM; RNA SEQUENCE; SIGNAL TRANSDUCTION; UPREGULATION; ACUTE MYELOID LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CHROMOSOME 16; CHROMOSOME 21; DIMERIZATION; DRUG EFFECTS; ENHANCER REGION; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; U-937 CELL LINE; ULTRASTRUCTURE;

AMINO ACID MOTIFS; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 21; DIMERIZATION; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MULTIPROTEIN COMPLEXES; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTO-ONCOGENE PROTEINS; RECEPTORS, RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOID X RECEPTORS; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA-BINDING PROTEIN FUS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC; TRETINOIN; U937 CELLS;

EID: 84935483565     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.261     Document Type: Article

References (54)

1. Sharrocks AD, Brown AL, Ling Y, Yates PR. The ETS-domain transcription factor family. Int J Biochem Cell Biol 1997; 29: 1371-1387.
2. Salek-Ardakani S, Smooha G, de Boer J, Sebire NJ, Morrow M, Rainis L et al. ERG is a megakaryocytic oncogene. Cancer Res 2009; 69: 4665-4673.
3. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
4. Sorensen PHB, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS - family transcription factor, ERG-EWS gene to another ETS - family transcription factor, ERG. Nat Genet 1994; 6: 146-151.
5. Yamamoto K, Hamaguchi H, Nagata K, Kobayashi M, Tanimoto F, Taniwaki M. Establishment of a novel human acute myeloblastic leukemia cell line (YNH-1) with t(16;21), t(1;16) and 12q13 translocations. Leukemia 1997; 11: 599-608.
6. Prasad DD, Ouchida M, Lee L, Rao VN, Reddy ES. TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain. Oncogene 1994; 9: 3717-3729.
7. Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993; 363: 640-644.
8. Zou J, Ichikawa H, Blackburn ML, Hu H-M, Zielinska-Kwiatkowska A, Mei Q et al. The oncogenic TLS-ERG fusion protein exerts different effects in hematopoietic cells and fibroblasts. Mol Cell Biol 2005; 25: 6235-6246.
9. Yang L, Embree LJ, Hickstein DD. TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins. Mol Cell Biol 2000; 20: 3345-3354.
10. Powers CA, Mathur M, Raaka BM, Ron D, Samuels HH. (TLS translocated-in-liposarcoma) is a high-affinity interactor for steroid, thyroid hormone, and retinoid receptors. Mol Endocrinol 1998; 12: 4-18.
11. Zinszner H, Immanuel D, Yin Y, Liang F-X, Ron D. A topogenic role for the oncogenic N-terminus of TLS: nucleolar localization when transcription is inhibited. Oncogene 1997; 14: 451-461.
12. Zinszner H, Sok J, Immanuel D, Yin Y, Ron D. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J Cell Sci 1997; 110: 1741-1750.
13. Delva L, Gallais I, Guillouf C, Denis N, Orvain C, Moreau-Gachelin F. Multiple functional domains of the oncoproteins Spi-1//PU.1 and TLS are involved in their opposite splicing effects in erythroleukemic cells. Oncogene 2004; 23: 4389-4399.
14. Hallier M, Lerga A, Barnache S, Tavitian A, Moreau-Gachelin F. The transcription factor Spi-1/PU.1 interacts with the potential splicing factor TLS. J Biol Chem 1998; 273: 4838-4842.
15. Mills KI, Walsh V, Gilkes AF, Sweeney MC, Mirza T, Woodgate LJ et al. High FUS/TLS expression in acute myeloid leukaemia samples. Br J Haematol 2000; 108: 316-321.
16. Walsby EJ, Gilkes AF, Tonks A, Darley RL, Mills KI. FUS expression alters the differentiation response to all-trans retinoic acid in NB4 and NB4R2 cells. Br J Haematol 2007; 139: 94-97.
17. Hicks GG, Singh N, Nashabi A, Mai S, Bozek G, Klewes L et al. Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat Genet 2000; 24: 175-179.
18. Sugawara T, Oguro H, Negishi M, Morita Y, Ichikawa H, Iseki T et al. FET family proto-oncogene Fus contributes to self-renewal of hematopoietic stem cells. Exp Hematol 2010; 38: 696-706.
19. Lian Z, Wang L, Yamaga S, Bonds W, Beazer-Barclay Y, Kluger Y et al. Genomic and proteomic analysis of the myeloid differentiation program. Blood 2001; 98: 513-524.
20. Martens JHA, Mandoli A, Simmer F, Wierenga B-J, Saeed S, Singh AA et al. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood 2012; 120: 4038-4048.
21. Bock J, Mochmann LH, Schlee C, Farhadi-Sartangi N, Gölner S, Müller-Tidow C et al. ERG transcriptional networks in primary acute leukemia cells implicate a role for ERG in deregulated kinase signaling. PLoS One 2013; 8: e52872.
22. Ng AP, Loughran SJ, Metcalf D, Hyland CD, de Graaf CA, Hu Y et al. Erg is required for self-renewal of hematopoietic stem cells during stress hematopoiesis in mice. Blood 2011; 118: 2454-2461.
23. Lacadie SA, Zon LI. The ERGonomics of hematopoietic stem cell self-renewal. Genes Dev 2011; 25: 289-293.
24. Loughran SJ, Kruse EA, Hacking DF, de Graaf CA, Hyland CD, Willson TA et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat Immunol 2008; 9: 810-819.
25. Goldberg L, Tijssen MR, Birger Y, Hannah RL, Kinston SJ, Schütte J et al. Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia. Blood 2013; 122: 2694-2703.
26. Kong X-T, Ida K, Ichikawa H, Shimizu K, Ohki M, Maseki N et al. Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16; 21)(p11; q22) and identification of a novel transcript. Blood 1997; 90: 1192-1199.
27. Winnes M, Lissbrant E, Damber J, Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 2007; 17: 1033-1036.
28. Wei G-H, Badis G, Berger MF, Kivioja T, Palin K, Enge M et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 2010; 29: 2147-2160.
29. Yu J, Yu J, Mani R-S, Cao Q, Brenner CJ, Cao X et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17: 443-454.
30. Zhang Y, Liu T, Meyer C, Eeckhoute J, Johnson D, Bernstein B et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 2008; 9: R137.
31. Kryndushkin D, Wickner R, Shewmaker F. FUS/TLS forms cytoplasmic aggregates, inhibits cell growth and interacts with TDP-43 in a yeast model of amyotrophic lateral sclerosis. Protein Cell 2011; 2: 223-236.
32. Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell 2000; 5: 811-820.
33. Boersema PJ, Raijmakers R, Lemeer S, Mohammed S, Heck AJR. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat Protoc 2009; 4: 484-494.
34. Wilson NK, Foster SD, Wang X, Knezevic K, Schütte J, Kaimakis P et al. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell 2010; 7: 532-544.
35. Diffner E, Beck D, Gudgin E, Thoms JAI, Knezevic K, Pridans C et al. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia. Blood 2013; 121: 2289-2300.
36. Beck D, Thoms JAI, Perera D, Schütte J, Unnikrishnan A, Knezevic K et al. Genome-wide analysis of transcriptional regulators in human HSPCs reveals a densely interconnected network of coding and noncoding genes. Blood 2013; 122: e12-e22.
37. Martens JHA, Brinkman AB, Simmer F, Francoijs K-J, Nebbioso A, Ferrara F et al. PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell 2010; 17: 173-185.
38. Ebralidze AK, Guibal FC, Steidl U, Zhang P, Lee S, Bartholdy B et al. PU.1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element. Genes Dev 2008; 22: 2085-2092.
39. Pereira DS, Dorrell C, Ito CY, Gan OI, Murdoch B, Rao VN et al. Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic cells. Proc Natl Acad Sci USA 1998; 95: 8239-8244.
40. Rapin N, Porse BT. Oncogenic fusion proteins expressed in immature hematopoietic cells fail to recapitulate the transcriptional changes observed in human AML. Oncogenesis 2014; 3: e106.
41. Drach J, McQueen T, Engel H, Andreeff M, Robertson KA, Collins SJ et al. Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-{alpha}. Cancer Res 1994; 54: 1746-1752.
42. Drach J, Zhao S, Malavasi F, Mehta K. Rapid induction of CD38 antigen on myeloid leukemia cells by all trans-retinoic acid. Biochem Biophys Res Commun 1993; 195: 545-550.
43. Dubois C, Schlageter M, de Gentile A, Guidez F, Balitrand N, Toubert M et al. Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells. Blood 1994; 83: 3264-3270.
44. Saeed S, Logie C, Stunnenberg HG, Martens JHA. Genome-wide functions of PMLRAR[ alpha] in acute promyelocytic leukaemia. Br J Cancer 2011; 104: 554-558.
45. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M et al. Fusion proteins of the retinoic acid receptor-[alpha] recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391: 815-818.
46. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811-814.
47. De Bellis F, Carafa V, Conte M, Rotili D, Petraglia F, Matarese F et al. Contextselective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392. Cancer Res 2014; 74: 2328-2339.
48. Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, Huynh L et al. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J Pharmacol Exp Ther 2007; 321: 953-960.
49. Saeed S, Logie C, Francoijs K-J, Frigè G, Romanenghi M, Nielsen FG et al. Chromatin accessibility, p300, and histone acetylation define PML-RARa and AML1-ETO binding sites in acute myeloid leukemia. Blood 2012; 120: 3058-3068.
50. Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J et al. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol 2011; 9: e1000614.
51. Shikami M, Miwa H, Nishii K, Takahashi T, Shiku H, Tsutani H et al. Myeloid differentiation antigen and cytokine receptor expression on acute myelocytic leukaemia cells with t(16;21)(p11;q22): frequent expression of CD56 and interleukin-2 receptor a chain. Br J Haematol 1999; 105: 711-719.
52. Denissov S, van Driel M, Voit R, Hekkelman M, Hulsen T, Hernandez N et al. Identification of novel functional TBP-binding sites and general factor repertoires. EMBO J 2007; 26: 944-954.
53. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
54. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078-2079.